Medication info
Olmesartan Medoxomil / Hydrochlorothiazide / Amlodipine Besylate Hydrate Tablets 2.5/40/12.5 mg

Olmesartan Medoxomil / Hydrochlorothiazide / Amlodipine Besylate Hydrate Tablets 2.5/40/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tabletS-Amlodipine Besylate Dihydrate›3.69mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
light yellow round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202401353 · Approved 2024.05.31 · Insurance code 653405760

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual ingredients (esamlo­dipine (amlodipine) and olmesartan medoxomil) as monotherapy or combination therapy. However, if blood pressure is not controlled with combination therapy of esamlodipine (amlodipine) and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40/25mg of esamlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses (in the order of esamlodipine/olmesartan medoxomil/hydrochlorothiazide) are as follows. - 2.5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of esamlodipine/olmesartan medoxomil 2.5/20mg (amlodipine/olmesartan medoxomil 5/20mg). - 2.5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of esamlodipine/olmesartan medoxomil 2.5/40mg (amlodipine/olmesartan medoxomil 5/40mg) or with this medicine 2.5/20/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). - 2.5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of esamlodipine/olmesartan medoxomil 5/40mg (amlodipine/olmesartan medoxomil 10/40mg) or with this medicine 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with esamlodipine/olmesartan medoxomil/hydrochlorothiazide 2.5/40/25mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/25mg) or with this medicine 5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 10/40/12.5mg). ※ Refer to the following dose-escalation schedule. The amounts of the individual ingredients are stated in the order of esamlodipine/olmesartan medoxomil/hydrochlorothiazide (amlodipine/olmesartan medoxomil/hydrochlorothiazide). 2.5/20/0mg (5/20/0mg) → 2.5/20/12.5mg (5/20/12.5mg) ↓ 2.5/40/0mg (5/40/0mg) → 2.5/40/12.5mg (5/40/12.5mg) → 2.5/40/25mg (5/40/25mg) ↓ ↓ 5/40/0mg (10/40/0mg) → 5/40/12.5mg (10/40/12.5mg) → 5/40/25mg (10/40/25mg) Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 2.5/20/12.5mg once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). In patients with moderate renal impairment, monitoring of potassium and creatinine levels is recommended. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 2.5/20/12.5mg once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years or older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. As there is very limited experience with the use of this medicine in elderly patients aged 75 years or older, monitor them very carefully when administering this medicine.
Child dose
The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

The combination therapy of Amlodipine (Amlodipine) and Olmesartan Medoxomil is suitable for patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy. The two components work together to dilate blood vessels and effectively lower blood pressure. This improves the condition of hypertensive patients who have difficulty controlling their blood pressure. Continuous use may also reduce the risk of cardiovascular complications. This treatment plays an important role in managing hypertension, thereby contributing to the maintenance of the patient’s health.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual ingredients (esamlo­dipine (amlodipine) and olmesartan medoxomil) as monotherapy or combination therapy. However, if blood pressure is not controlled with combination therapy of esamlodipine (amlodipine) and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40/25mg of esamlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses (in the order of esamlodipine/olmesartan medoxomil/hydrochlorothiazide) are as follows. - 2.5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of esamlodipine/olmesartan medoxomil 2.5/20mg (amlodipine/olmesartan medoxomil 5/20mg). - 2.5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of esamlodipine/olmesartan medoxomil 2.5/40mg (amlodipine/olmesartan medoxomil 5/40mg) or with this medicine 2.5/20/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). - 2.5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of esamlodipine/olmesartan medoxomil 5/40mg (amlodipine/olmesartan medoxomil 10/40mg) or with this medicine 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with esamlodipine/olmesartan medoxomil/hydrochlorothiazide 2.5/40/25mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/25mg) or with this medicine 5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 10/40/12.5mg). ※ Refer to the following dose-escalation schedule. The amounts of the individual ingredients are stated in the order of esamlodipine/olmesartan medoxomil/hydrochlorothiazide (amlodipine/olmesartan medoxomil/hydrochlorothiazide). 2.5/20/0mg (5/20/0mg) → 2.5/20/12.5mg (5/20/12.5mg) ↓ 2.5/40/0mg (5/40/0mg) → 2.5/40/12.5mg (5/40/12.5mg) → 2.5/40/25mg (5/40/25mg) ↓ ↓ 5/40/0mg (10/40/0mg) → 5/40/12.5mg (10/40/12.5mg) → 5/40/25mg (10/40/25mg) Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 2.5/20/12.5mg once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). In patients with moderate renal impairment, monitoring of potassium and creatinine levels is recommended. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 2.5/20/12.5mg once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years or older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. As there is very limited experience with the use of this medicine in elderly patients aged 75 years or older, monitor them very carefully when administering this medicine.

Child dose

The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, therefore it should be discontinued immediately if pregnancy is confirmed. It is safer not to use this medication if there is an allergy or hypersensitivity to any of the ingredients or similar medications. Patients with severe hypotension, severe heart valve disease, unstable heart failure after acute myocardial infarction, or severe renal or liver dysfunction should avoid taking this medication. In cases of reduced salt or blood volume, blood pressure may drop excessively in the early stages of taking this medication; thus, monitoring the condition before and during treatment is essential. Patients with renal impairment or those who have received a kidney transplant should have regular tests of kidney function and blood electrolyte levels while taking this medication. Patients with severely impaired liver function or specific heart diseases also need to use this medication with caution. This medication has a blood pressure-lowering effect; therefore, dizziness or drowsiness may occur during activities requiring careful attention, such as operating machinery or driving. Regular blood tests to check electrolytes and renal function are essential while taking this medication. Patients with diabetes or gout should closely manage changes in blood sugar and uric acid levels while taking this medication. In photosensitivity reactions may occur, care should be taken to avoid excessive exposure to sunlight or ultraviolet rays, and if any abnormal symptoms appear, immediate consultation with a physician is advised. This medication is not recommended for breastfeeding women, and consultation with a physician is required if breastfeeding persists, as it may affect the baby. Safety and efficacy have not been established for patients under 18 years of age, and its use should be avoided. Seniors may have decreased kidney and liver function, so they should adjust the dosage and be attentive to side effects while taking it. In the case of overdose, symptoms such as hypotension, palpitations, and bradycardia may occur, and immediate medical attention is necessary.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusional state, depression, apathy, sensitivity to stimuli, anxiety, mood changes, sleep disturbances, vertigo, orthostatic dizziness, syncope, taste disturbances, hypertension, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, reduced tears, worsening of myopia, jaundice, lightheadedness, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, alopecia, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, phototoxic reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle cramping, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urination, acute renal failure, hematuria, micturition disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, intestinal vascular edema, drug hypersensitivity, upper abdominal pain, decreased libido, scrotal edema, asthenia, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, choroidal exudate, acute respiratory distress syndrome (ARDS)

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best kept at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

light yellow round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.